Polypharmacy in heart failure patients

被引:66
|
作者
Mastromarino V. [1 ]
Casenghi M. [1 ]
Testa M. [1 ]
Gabriele E. [1 ]
Coluccia R. [1 ]
Rubattu S. [1 ,2 ]
Volpe M. [1 ,2 ]
机构
[1] Clinical and Molecular Medicine Department, Sapienza University of Rome, Ospedale Sant' Andrea, 00189 Rome
[2] IRCCS Neuromed, Pozzilli, IS
关键词
Adherence; Brain natriuretic peptide; Comorbidities; Heart failure; Polypharmacy; Self-care;
D O I
10.1007/s11897-014-0186-8
中图分类号
学科分类号
摘要
In heart failure (HF), the progressive use of multiple drugs and a complex therapeutic regimen is common and is recommended by international guidelines.With HF being a common disease in the elderly, patients often have numerous comorbidities that require additional specific treatment, thus producing a heavy pill burden. Polypharmacy, defined as the chronic use of five or more medications, is an underestimated problem in the management of HF patients. However, polypharmacy has an important impact on HF treatment, as it often leads to inappropriate drug prescription, poor adherence to pharmacological therapies, drug-drug interactions, and adverse effects. The growing complexity of HF patients, whose mean age increases progressively and who present multiple comorbidities, suggests the need for newer models of primary care to improve the management of HF patients. Self-care, telemonitoring, and natriuretic peptide-guided therapy represent promising new HF care models to face the complexity of the disease and its therapeutic regimen. © Springer Science+Business Media 2014.
引用
收藏
页码:212 / 219
页数:7
相关论文
共 50 条
  • [1] Polypharmacy in patients with chronic heart failure
    Gaman, M. A. Mihnea-Alexandru
    Dobrica, E. C.
    Cozma, M. A.
    Gaman, A. M.
    Diaconu, C. C.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 421 - 422
  • [2] Prognostic value of polypharmacy in patients with heart failure
    Fujita, R.
    Takabayashi, K.
    Iwatsu, K.
    Matsumura, K.
    Ikeda, T.
    Kitaguchi, S.
    Nohara, R.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 3962 - 3962
  • [3] Polypharmacy and taste disorders in heart failure patients
    Kinugasa, Yoshiharu
    Nakayama, Natsuko
    Sugihara, Shinobu
    Mizuta, Einosuke
    Nakamura, Kensuke
    Kamitani, Hiroko
    Hirai, Masayuki
    Yanagihara, Kiyotaka
    Kato, Masahiko
    Yamamoto, Kazuhiro
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (01) : 110 - 111
  • [4] And an ARB makes nine: Polypharmacy in patients with heart failure
    Stehlik, J
    Taylor, DO
    [J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 2004, 71 (08) : 674 - 677
  • [5] Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach
    Sukumar, Smrithi
    Orkaby, Ariela R.
    Schwartz, Janice B.
    Marcum, Zachary
    Januzzi, James L.
    Vaduganathan, Muthiah
    Warraich, Haider J.
    [J]. CURRENT HEART FAILURE REPORTS, 2022, 19 (05) : 290 - 302
  • [6] Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach
    Smrithi Sukumar
    Ariela R. Orkaby
    Janice B. Schwartz
    Zachary Marcum
    James L. Januzzi
    Muthiah Vaduganathan
    Haider J. Warraich
    [J]. Current Heart Failure Reports, 2022, 19 : 290 - 302
  • [7] The problem of polypharmacy in heart failure
    Flesch M.
    Erdmann E.
    [J]. Current Cardiology Reports, 2006, 8 (3) : 217 - 225
  • [8] The Effect Of Polypharmacy And Polypharmacy Risk On Patients Admitted With Heart Failure With Preserved Ejection Fraction
    Farooq, Awais
    Kulkarni, Sagar
    Foster, Brian
    Liaqat, Adnan
    Farooq, Shahryar
    Tosto, Sebastian
    Razzouk, Elie
    [J]. JOURNAL OF CARDIAC FAILURE, 2023, 29 (04) : 669 - 669
  • [9] Heart Failure Research and Polypharmacy
    Somberg, John
    [J]. CARDIOLOGY RESEARCH, 2022, 13 (01) : 1 - 1
  • [10] Heart failure patients in Primary Care: aging, comorbidities and polypharmacy
    Galindo Ortego, Gisela
    Cruz Esteve, Ines
    Real Gatius, Jordi
    Galvan Santiago, Leonardo
    Monso Lacruz, Carmen
    Santafe Soler, Placido
    [J]. ATENCION PRIMARIA, 2011, 43 (02): : 61 - 67